Other Events ·
ArriVent BioPharma Phase 3 FURVENT trial of firmonertinib misses primary PFS endpoint
AVBPArriVent BioPharma, Inc.
ArriVent BioPharma announced that its Phase 3 FURVENT trial evaluating firmonertinib monotherapy in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet the primary endpoint of progression-free survival by blinded independent central review. While secondary endpoints showed clinical benefit, including a confirmed objective response rate of 60% for the 240mg dose versus 33% for control, the drug failed to demonstrate a statistically significant improvement over chemotherapy in the primary measure. The company is evaluating the full dataset to determine the future development path for firmonertinib. ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer.